CoChat

Mitochonic Acid 5 Binds Mitochondria and Ameliorates Renal Tubular and Cardiac Myocyte Damage

Open access
Suzuki, Takehiro, Yamaguchi, Hiroaki, Kikusato, Motoi, Hashizume, Osamu, Nagatoishi, Satoru, Matsuo, Akihiro, Sato, Takeya, Kudo, Tai, Matsuhashi, Tetsuro, Murayama, Kazutaka, Ohba, Yuki, Watanabe, Shun, Kanno, Shin-ichiro, Minaki, Daichi, Saigusa, Daisuke, Shinbo, Hiroko, Mori, Nobuyoshi, Yuri, Akinori, Yokoro, Miyuki, Mishima, Eikan, Shima, Hisato, Akiyama, Yasutoshi, Takeuchi, Yoichi, Kikuchi, Koichi, Toyohara, Takafumi, Suzuki, Chitose, Ichimura, Takaharu, Anzai, Jun-ichi, Kohzuki, Masahiro, Mano, Nariyasu, Kure, Shigeo, Yanagisawa, Teruyuki, Tomioka, Yoshihisa, Toyomizu, Masaaki, Tsumoto, Kohei, Nakada, Kazuto, Bonventre, Joseph V., Ito, Sadayoshi, Osaka, Hitoshi, Hayashi, Ken-ichi, Abe, Takaaki · 2016 · Journal of the American Society of Nephrology
Cited by 85

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Mitochondrial dysfunction causes increased oxidative stress and depletion of ATP, which are involved in the etiology of a variety of renal diseases, such as CKD, AKI, and steroid–resistant nephrotic syndrome. Antioxidant therapies are being investigated, but clinical outcomes have yet to be determined. Recently, we reported that a newly synthesized indole derivative, mitochonic acid 5 (MA-5), increases cellular ATP level and survival of fibroblasts from patients with mitochondrial disease. MA-5 modulates mitochondrial ATP synthesis independently of oxidative phosphorylation and the electron transport chain. Here, we further investigated the mechanism of action for MA-5. Administration of MA-5 to an ischemia-reperfusion injury model and a cisplatin–induced nephropathy model improved renal function. In in vitro bioenergetic studies, MA-5 facilitated ATP production and reduced the level of mitochondrial reactive oxygen species (ROS) without affecting activity of mitochondrial complexes I–IV. Additional assays revealed that MA-5 targets the mitochondrial protein mitofilin at the crista junction of the inner membrane. In Hep3B cells, overexpression of mitofilin increased the basal ATP level, and treatment with MA-5 amplified this effect. In a unique mitochondrial disease model (Mitomice with mitochondrial DNA deletion that mimics typical human mitochondrial disease phenotype), MA-5 improved the reduced cardiac and renal mitochondrial respiration and seemed to prolong survival, although statistical analysis of survival times could not be conducted. These results suggest that MA-5 functions in a manner differing from that of antioxidant therapy and could be a novel therapeutic drug for the treatment of cardiac and renal diseases associated with mitochondrial dysfunction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2015060623

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 85

Metadata

Authors
Suzuki, T., Yamaguchi, H., Kikusato, M., Hashizume, O., Nagatoishi, S., Matsuo, A., Sato, T., Kudo, T., Matsuhashi, T., Murayama, K., Ohba, Y., Watanabe, S., Kanno, S.-I., Minaki, D., Saigusa, D., Shinbo, H., Mori, N., Yuri, A., Yokoro, M., Mishima, E., Shima, H., Akiyama, Y., Takeuchi, Y., Kikuchi, K., Toyohara, T., Suzuki, C., Ichimura, T., Anzai, J.-I., Kohzuki, M., Mano, N., Kure, S., Yanagisawa, T., Tomioka, Y., Toyomizu, M., Tsumoto, K., Nakada, K., Bonventre, J. V., Ito, S., Osaka, H., Hayashi, K.-I., & Abe, T.
Venue
Journal of the American Society of Nephrology
Published
2015-11-25
Volume
27
Issue
7
Pages
1925-1932
ISSN
  • 1046-6673 (ISSN-L)
  • 1533-3450
OpenAlex
W2177819816
Cited by
85
References
2
FWCI
2.44
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.